David J. Benjamin: The importance of patient selection criteria in treating advanced urothelial carcinoma
David J. Benjamin shared a post on X:
“In European Urology Oncology, Arash Rezazadeh and I discuss the importance of patient selection criteria for determining the most appropriate regimen (EV-302 vs. CheckMate 901 vs. JAVELIN Bladder 100) in treating advanced urothelial carcinoma.”
Authors: David J. Benjamin and Arash Rezazadeh Kalebasty.
Dr. Benjamin enjoys working alongside a team of experts in the cancer field to provide high-quality, personal care to patients as a board-certified medical oncologist at Hoag Family Cancer Center. His practice focuses on genitourinary cancers, including prostate, bladder, kidney and testicular cancer.
Dr. Benjamin has co-authored numerous publications in leading medical journals, including JAMA Oncology, The Lancet Oncology and Nature Reviews Urology. He has presented his research at several national and international conferences. He received the 2022 Genitourinary Cancers Symposium Merit Award from Conquer Cancer, the ASCO Foundation, and received the 2022 UCI School of Medicine Outstanding Fellow/Resident Research Award for excellence in clinical/translational research. Dr. Benjamin is a member of the American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023